People · Operator
Named in public records as an officer, director or promoter · active 2010–2024 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Nemus Bioscience, Inc. | — | Pharmaceuticals | Series C | $168.4M | $388.3M | 2023 |
| Eyegate Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $72.9M | $92.5M | 2010 |
| Maxwell Biosciences, Inc. | — | Biotechnology | Series B | $35.9M | $269.7M | 2021 |
| Orion Biotechnology Canada Ltd. | — | Biotechnology | Series A | $11.2M | $3.9M | 2024 |
| Gila Therapeutics, Inc. | — | Biotechnology | Seed | $6.2M | $2.7M | 2023 |
Praveen Tyle at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Praveen Tyle on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| Annalisa Jenkins | 1 | 8 |
| Timothy Barberich | 1 | 6 |
| Jon Freeman | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| Punit Dhillon | 1 | 4 |
| Eric Daniels | 1 | 4 |
| Steven Boyd | 1 | 3 |
| Thomas E. Hancock | 1 | 3 |
| Sarah Romano | 1 | 3 |
| Gerald W. McLaughlin | 1 | 3 |
| Peter Greenleaf | 1 | 3 |
| Douglas S. Ingram | 1 | 3 |
| David Hollander | 1 | 3 |
| Keith Ward | 1 | 3 |
| Richard Horan | 1 | 2 |
| J. Sebastien Cleiftie | 1 | 2 |
| Stephen From | 1 | 2 |
| Paul Chaney | 1 | 2 |
| Lonnel Coats | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.